Literature DB >> 18460264

Drug-induced osteoporosis: beyond glucocorticoids.

Karine Briot1, Christian Roux.   

Abstract

To prevent osteoporotic fractures, it is important to identify patients at high risk of fracture by assessing risk factors such as underlying diseases and drugs. Prior and current use of oral corticosteroids is strongly associated with increased fracture risk, but other medications could be involved and should be assessed as part of the optimal care of patients at risk of osteoporosis. Strong evidence points to gonadotropin-releasing hormone agonists, aromatase inhibitors, and antiepileptic drugs. Further studies are necessary to confirm the deleterious effect of other treatments on bone.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18460264     DOI: 10.1007/s11926-008-0019-4

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  66 in total

1.  Exposure to tricyclic and selective serotonin reuptake inhibitor antidepressants and the risk of hip fracture.

Authors:  Richard Hubbard; Paddy Farrington; Chris Smith; Liam Smeeth; Anne Tattersfield
Journal:  Am J Epidemiol       Date:  2003-07-01       Impact factor: 4.897

2.  Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture.

Authors:  P Vestergaard; L Rejnmark; L Mosekilde
Journal:  Osteoporos Int       Date:  2006-03-07       Impact factor: 4.507

3.  Fracture risk in users of oral anticoagulants: a nationwide case-control study.

Authors:  Lars Rejnmark; Peter Vestergaard; Leif Mosekilde
Journal:  Int J Cardiol       Date:  2006-10-18       Impact factor: 4.164

4.  Fracture risk associated with the use of morphine and opiates.

Authors:  P Vestergaard; L Rejnmark; L Mosekilde
Journal:  J Intern Med       Date:  2006-07       Impact factor: 8.989

5.  Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra) on human osteoblasts in vitro.

Authors:  A E Handschin; O A Trentz; S P Hoerstrup; H J Kock; G A Wanner; O Trentz
Journal:  Br J Surg       Date:  2005-02       Impact factor: 6.939

6.  Progressive osteoporosis during androgen deprivation therapy for prostate cancer.

Authors:  H W Daniell; S R Dunn; D W Ferguson; G Lomas; Z Niazi; P T Stratte
Journal:  J Urol       Date:  2000-01       Impact factor: 7.450

7.  Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia?

Authors:  Veronica O'Keane; Anna Maria Meaney
Journal:  J Clin Psychopharmacol       Date:  2005-02       Impact factor: 3.153

8.  Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis.

Authors:  J Faber; A M Galløe
Journal:  Eur J Endocrinol       Date:  1994-04       Impact factor: 6.664

Review 9.  Hydroxylase enzymes of the vitamin D pathway: expression, function, and regulation.

Authors:  John L Omdahl; Howard A Morris; Brian K May
Journal:  Annu Rev Nutr       Date:  2002-01-04       Impact factor: 11.848

10.  Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.

Authors:  M Dror Michaelson; Donald S Kaufman; Hang Lee; Francis J McGovern; Philip W Kantoff; Mary Anne Fallon; Joel S Finkelstein; Matthew R Smith
Journal:  J Clin Oncol       Date:  2007-03-20       Impact factor: 44.544

View more
  7 in total

Review 1.  [Pathophysiology of bone metabolism].

Authors:  F Jakob; L Seefried; R Ebert
Journal:  Internist (Berl)       Date:  2008-10       Impact factor: 0.743

2.  Impaired skeletal health and neuromuscular function among amphetamine users in clinical treatment.

Authors:  M P Mosti; G Flemmen; J Hoff; A K Stunes; U Syversen; E Wang
Journal:  Osteoporos Int       Date:  2015-10-26       Impact factor: 4.507

3.  A practical approach to osteoporosis management in the geriatric population.

Authors:  Dan Liberman; Angela Cheung
Journal:  Can Geriatr J       Date:  2015-03-31

4.  Assessment of bone metabolism and biomechanical properties of the femur, following treatment with anastrozole and letrozole in an experimental model of menopause.

Authors:  Ioannis Boutas; Vasilios Pergialiotis; Nicolaos Salakos; Laskarina-Maria Korou; Athanasios Mitousoudis; Emmanouil Kalampokas; Efthimios Deligeoroglou; Odysseas Gregoriou; Despina N Perrea; George Creatsas; Stavros Kourkoulis
Journal:  Oncol Lett       Date:  2017-07-18       Impact factor: 2.967

Review 5.  Dental implants in Sjögren's syndrome patients: A systematic review.

Authors:  Daniel Almeida; Katia Vianna; Patrícia Arriaga; Vittorio Moraschini
Journal:  PLoS One       Date:  2017-12-14       Impact factor: 3.240

6.  Risk factors and epidemiological profile of hip fractures in Indian population: A case-control study.

Authors:  Kaustubh Ahuja; Sagnik Sen; Dinesh Dhanwal
Journal:  Osteoporos Sarcopenia       Date:  2017-09-27

Review 7.  Long Non-coding RNAs: A New Regulatory Code for Osteoporosis.

Authors:  Qian-Yuan Wu; Xia Li; Zong-Ning Miao; Jun-Xing Ye; Bei Wang; Feng Zhang; Rui-Sheng Xu; Dong-Lin Jiang; Ming-Dong Zhao; Feng Lai Yuan
Journal:  Front Endocrinol (Lausanne)       Date:  2018-10-04       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.